Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

Journal for ImmunoTherapy of Cancer

Stuart Seropian¹  Mario Sznol¹  Michael Cecchini¹ 

[1] Division of Medical Oncology, Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital Yale University School of Medicine, New Haven, USA

关键词: Programmed cell death 1 receptor and immune-related adverse events;    CTLA-4 antigen;    Ipilimumab;    Allogeneic transplant;    Graft vs host disease;    Interleukin-2;    Immunotherapy;    Melanoma;   

Others  :  1144112
DOI  :  10.1186/s40425-015-0054-4

 received in 2014-12-14, accepted in 2015-02-25,  发布年份 2015

【 摘 要 】

Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD.

【 授权许可】

   
2015 Cecchini et al.; licensee BioMed Central.

【 参考文献 】

• [1]Curtis RE, et al.: Solid Cancers after Bone Marrow Transplantation. N Engl J Med 1997, 336(13):897-904.
• [2]Kaufman H, et al.: The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013, 10(10):588-598.
• [3]Blazar BR, et al.: Opposing Roles of CD28:B7 and CTLA-4:B7 Pathways in Regulating In Vivo Alloresponses in Murine Recipients of MHC Disparate T Cells. J Immunol 1999, 162(11):6368-6377.
• [4]Blazar BR, et al.: Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN- -Dependent Mechanism. J Immunol 2003, 171(3):1272-1277.
• [5]Bashey A, et al.: CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009, 113(7):1581-1588.
• [6]Zhou J, et al.: CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant 2011, 17(5):682-692.
• [7]Saranga-Perry V, et al.: Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin 2014, 64(3):171-185.
• [8]Hodi FS, et al.: Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010, 363(8):711-723.
• [9]Pavletic SZ, Fowler DH: Are we making progress in GVHD prophylaxis and treatment? ASH Education Program Book 2012, 2012(1):251-264.
• [10]Flowers, M.E.D., Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria, ed. M.E.D. Flowers, et al. Vol. 117. 2011. 3214–3219.